Moleculin Biotech shareholders approve equity plan expansion

Moleculin Biotech said shareholders approved amendments to its 2024 Equity Plan at the company’s annual meeting. The changes increase shares authorized for issuance under the plan by 3,861,894 to 3,875,999.